Management of Chronic Kidney Disease Stages 1–3
Conclusions: Treatment (2 of 2)
Statins reduced the risk for mortality, myocardial infarction, and stroke in patients with hyperlipidemia and impaired eGFR, and beta-blockers may reduce mortality in patients with congestive heart failure and impaired eGFR. In the included trials, many patients for whom improved outcomes were observed had a pre-existing clinical indication for the treatment studied regardless of CKD status.
Adverse effects were reported in only a few randomized clinical trials and did not permit conclusions. The adverse events reported generally were consistent with the known potential adverse effects of these treatments (e.g., hypotension with antihypertensive medications, cough with ACEIs, hyperkalemia with ACEIs and ARBs).
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate
- Fink HA, Ishani A, Taylor BC, et al. Chronic Kidney Disease Stages 1–3: Screening, Monitoring, and Treatment. Comparative Effectiveness Review No. 37 (Prepared by the Minnesota Evidence-based Practice Center under Contract No. HHSA 290-2007-10064-I). Rockville, MD: Agency for Healthcare Research and Quality; January 2012. AHRQ Publication No. 11(12)-EHC075-EF. Available at www.effectivehealthcare.ahrq.gov/ckd.cfm.
Your slide tray is being processed.